Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

8.20USD
4:00pm EDT
Change (% chg)

$0.75 (+10.07%)
Prev Close
$7.45
Open
$7.40
Day's High
$8.27
Day's Low
$7.40
Volume
259,427
Avg. Vol
168,564
52-wk High
$8.57
52-wk Low
$2.65

SGMO.OQ

Chart for SGMO.OQ

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 3.29
Market Cap(Mil.): $535.95
Shares Outstanding(Mil.): 71.94
Dividend: --
Yield (%): --

Financials

  SGMO.OQ Industry Sector
P/E (TTM): -- 139.31 17.29
EPS (TTM): -1.02 -- --
ROI: -44.77 2.29 -5.84
ROE: -47.07 0.06 -5.23

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.

May 10 2017

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK, May 10 U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.

May 10 2017

BRIEF-Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy

* Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy

May 10 2017

BRIEF-Sangamo announces retirement of its founder Edward Lanphier from board

* Sangamo announces the retirement of its founder and genome editing pioneer Edward Lanphier from the board of directors Source text for Eikon: Further company coverage:

Apr 25 2017

BRIEF-Sangamo Therapeutics announces presentation of new data

* Sangamo Therapeutics announces presentation of new data demonstrating significant reduction of TAU expression using proprietary ZFP gene regulation technology

Mar 29 2017

BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-913 genome editing treatment for MPS II

* Sangamo Therapeutics receives orphan drug designation from the fda for sb-913 genome editing treatment for mps ii

Mar 01 2017

BRIEF-Sangamo Therapeutics announces CFO succession

* Sangamo Therapeutics announces chief financial officer succession

Feb 27 2017

More From Around the Web

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.277.30 +0.20
Pfizer Inc. (PFE.N) $32.14 +0.02
Novartis AG (NOVN.S) CHF79.05 -0.35
Merck & Co., Inc. (MRK.N) $64.55 +0.51
Roche Holding Ltd. (ROG.S) CHF267.90 0.00
Roche Holding Ltd. (RO.S) CHF267.25 -0.50
Bayer AG (BAYGn.DE) €118.05 +1.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.82 +0.07
GlaxoSmithKline plc (GSK.L) 1,629.50 -12.50

Earnings vs. Estimates